Overview
Suguru Morimoto practices practicing medicine in Kyoto, Japan.
Their clinical expertise encompasses Autoimmune Hemolytic Anemia, Acute Promyelocytic Leukemia, and Diffuse Large B-Cell Lymphoma (DLBCL).
They are actively involved in clinical research, co-authoring 8 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Suguru Morimoto
Is Suguru Morimoto a top-rated expert for Autoimmune Hemolytic Anemia?
MediFind is an objective health platform that identifies experts based on real-world data. Suguru Morimoto is classified as an Experienced expert for Autoimmune Hemolytic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Suguru Morimoto participate in research or clinical trials?
Yes. Suguru Morimoto has published 8 articles and abstracts on conditions like Autoimmune Hemolytic Anemia. You can view a list of Suguru Morimoto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Promyelocytic LeukemiaMorimoto isExperienced. Learn about Acute Promyelocytic Leukemia.
- Autoimmune Hemolytic AnemiaMorimoto isExperienced. Learn about Autoimmune Hemolytic Anemia.
- Diffuse Large B-Cell Lymphoma (DLBCL)